100+ datasets found
  1. m

    Rheumatoid Arthritis Drugs Market Size & Share Analysis - Industry Research...

    • mordorintelligence.com
    pdf,excel,csv,ppt
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Mordor Intelligence, Rheumatoid Arthritis Drugs Market Size & Share Analysis - Industry Research Report - Growth Trends [Dataset]. https://www.mordorintelligence.com/industry-reports/rheumatoid-arthritis-drugs-market
    Explore at:
    pdf,excel,csv,pptAvailable download formats
    Dataset authored and provided by
    Mordor Intelligence
    License

    https://www.mordorintelligence.com/privacy-policyhttps://www.mordorintelligence.com/privacy-policy

    Time period covered
    2019 - 2030
    Area covered
    Global
    Description

    The Rheumatoid Arthritis Drugs Market report segments the industry into By Type Of Molecule (Pharmaceuticals, Biopharmaceuticals), By Drug Class (Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Disease-Modifying Antirheumatic Drugs (DMARDs), Corticosteroids, Analgesics, Other Drug Classes), By Sales Channel (Prescription, Over-The-Counter (OTC)), and Geography (North America, Europe, Asia-Pacific, and more).

  2. L

    Rheumatology Therapeutics Market

    • transparencymarketresearch.com
    csv, pdf
    Updated Apr 2, 2024
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Transparency Market Research (2024). Rheumatology Therapeutics Market [Dataset]. https://www.transparencymarketresearch.com/rheumatology-therapeutics-market.html
    Explore at:
    pdf, csvAvailable download formats
    Dataset updated
    Apr 2, 2024
    Dataset authored and provided by
    Transparency Market Research
    License

    https://www.transparencymarketresearch.com/privacy-policy.htmlhttps://www.transparencymarketresearch.com/privacy-policy.html

    Time period covered
    2024 - 2034
    Area covered
    Worldwide
    Description
    • The global industry was valued at US$ 48.8 Bn in 2023
    • It is estimated to grow at a CAGR of 2.6% from 2024 to 2034 and reach 65.1 Bn by the end of 2034

    Market Introduction

    AttributeDetail
    Drivers
    • Rise in Prevalence of Rheumatoid Arthritis
    • R&D of Disease-modifying Therapies

    Regional Outlook

    AttributeDetail
    Leading RegionNorth America

    Rheumatology Therapeutics Market Snapshot

    AttributeDetail
    Market Size in 2023US$ 48.8 Bn
    Market Forecast (Value) in 2034US$ 65.1 Bn
    Growth Rate (CAGR)2.6%
    Forecast Period2024-2034
    Historical Data Available for2017-2021
    Quantitative UnitsUS$ Bn for Value
    Market AnalysisIt includes segment analysis as well as regional level analysis. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces Analysis, value chain analysis, and key trend analysis.
    Competition Landscape
    • Market share analysis by company (2023)
    • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy and recent developments, and key financials
    FormatElectronic (PDF) + Excel
    Market Segmentation
    • By Drug Class
      • Disease Modifying Anti-rheumatic Drugs (DMARDs)
        • Synthetic Disease Modifying Anti-rheumatic Drugs
        • Biologic Disease Modifying Anti-rheumatic Drugs
      • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
      • Corticosteroids
      • Uric Acid Drugs
      • Others
    • By Disease Indication
      • Rheumatoid Arthritis
      • Osteoarthritis
      • Gout
      • Psoriatic Arthritis
      • Ankylosing Spondylitis
      • Others
    • By Route of Administration
      • Parenteral Route
      • Oral Route
      • Topical
    • By Distribution Channel
      • Hospital Pharmacy
      • Retail Pharmacy
      • Online Pharmacy
    Regions Covered
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East & Africa
    Countries Covered
    • U.S.
    • Canada
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Japan
    • China
    • India
    • Australia & New Zealand
    • Brazil
    • Mexico
    • South Africa
    • GCC Countries
    Companies Profiled
    • Merck & Co., Inc.
    • AbbVie, Inc.
    • Bristol-Myers Squibb Company
    • Pfizer, Inc.
    • Takeda Pharmaceutical Company Limited
    • Amgen, Inc.
    • Genentech, Inc.
    • Novartis AG
    • Johnson & Johnson Innovative Medicine
    • F. Hoffmann-La Roche AG
    • Sanofi
    Customization ScopeAvailable upon request
    PricingAvailable upon request
  3. D

    Rheumatology Drugs Market Report | Global Forecast From 2025 To 2033

    • dataintelo.com
    csv, pdf, pptx
    Updated Dec 3, 2024
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Dataintelo (2024). Rheumatology Drugs Market Report | Global Forecast From 2025 To 2033 [Dataset]. https://dataintelo.com/report/global-rheumatology-drugs-market
    Explore at:
    pdf, csv, pptxAvailable download formats
    Dataset updated
    Dec 3, 2024
    Dataset authored and provided by
    Dataintelo
    License

    https://dataintelo.com/privacy-and-policyhttps://dataintelo.com/privacy-and-policy

    Time period covered
    2024 - 2032
    Area covered
    Global
    Description

    Rheumatology Drugs Market Outlook



    The global rheumatology drugs market size was valued at approximately USD 61 billion in 2023 and is projected to reach around USD 112 billion by 2032, expanding at a compound annual growth rate (CAGR) of 7.1% during the forecast period. This robust growth is fueled by an increasing prevalence of rheumatic diseases worldwide and a growing aging population, which is more susceptible to chronic ailments. The advancement in biologics and biosimilars, coupled with an increasing focus on novel therapeutic drugs, is transforming the landscape of rheumatology treatments. Additionally, the rising awareness about these conditions and an increase in healthcare expenditure are significant factors contributing to the market's expansion.



    One of the primary growth drivers for the rheumatology drugs market is the escalating incidence of rheumatic disorders such as rheumatoid arthritis, osteoarthritis, gout, and lupus. These conditions are becoming more prevalent due to lifestyle changes, increasing rates of obesity, and a growing geriatric population. As a result, there is a heightened demand for effective treatments that can manage symptoms and improve the quality of life for patients. The market is also witnessing a surge in research and development activities aimed at discovering advanced and more efficient treatments. Pharmaceutical companies are investing heavily in R&D to develop biologics and biosimilars that can target the immune system more precisely and offer better outcomes with fewer side effects.



    Moreover, technological advancements in drug delivery systems and the advent of personalized medicine are opening new avenues for market growth. The integration of artificial intelligence and machine learning in drug discovery processes is leading to the rapid identification of potential drug candidates, thereby accelerating the development pipeline. Personalized medicine, which tailors treatment to individual genetic profiles, is gaining traction, especially in rheumatology, where genetic factors play a crucial role in disease progression and treatment response. This shift towards personalized and precision medicine is expected to significantly drive the demand for innovative rheumatology drugs over the forecast period.



    The regional outlook of the rheumatology drugs market reveals that North America holds the largest market share, attributed to the high prevalence of rheumatic diseases, advanced healthcare infrastructure, and significant investment in R&D activities. The presence of key market players and favorable reimbursement policies further bolster the market in this region. Europe, with its aging population and increasing prevalence of arthritis, is also a significant market. The Asia Pacific region is poised for rapid growth due to improving healthcare facilities, rising awareness, and increasing healthcare expenditure. Meanwhile, Latin America and the Middle East & Africa are emerging markets with immense potential, driven by rising incidences of rheumatic diseases and improving access to healthcare services.



    Drug Type Analysis



    The drug type segment of the rheumatology drugs market is categorized into Disease-Modifying Anti-Rheumatic Drugs (DMARDs), Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), corticosteroids, biologics, and others. DMARDs are a cornerstone in the treatment of rheumatic diseases, particularly rheumatoid arthritis. They work by slowing down disease progression and modifying the immune response, which can help control the disease and prevent joint damage. The market for DMARDs is expected to grow steadily, driven by ongoing advancements and improvements in drug formulations that enhance patient compliance and therapeutic outcomes.



    NSAIDs are commonly used for pain relief and inflammation control in various rheumatic conditions. These drugs are often the first line of treatment for managing mild to moderate symptoms, making them a vital component of the rheumatology drugs market. Despite their widespread use, the market for NSAIDs faces challenges due to potential side effects associated with long-term use, such as gastrointestinal issues and cardiovascular risks. However, the development of new NSAID formulations with improved safety profiles is expected to sustain demand in this segment.



    Corticosteroids, known for their potent anti-inflammatory properties, are used for quick relief of acute symptoms in rheumatic diseases. They are often prescribed in conjunction with other medications to manage flare-ups effectively. While their use is declining due to potential side effects from prolonged use, inc

  4. s

    Global Rheumatoid Arthritis Drugs Market Size, Share, Growth Analysis, By...

    • skyquestt.com
    Updated Dec 9, 2024
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    SkyQuest Technology (2024). Global Rheumatoid Arthritis Drugs Market Size, Share, Growth Analysis, By Drug Class(Disease-modifying Anti-rheumatic Drugs, Nonsteroidal Anti-inflammatory Drugs), By Route of Administration(Oral, Parenteral), By Sales Channel(Prescription-based Drugs, Over-the-counter Drugs), By Molecule(Pharmaceuticals and Biopharmaceuticals) - Industry Forecast 2023-2030 [Dataset]. https://www.skyquestt.com/report/rheumatoid-arthritis-drugs-market
    Explore at:
    Dataset updated
    Dec 9, 2024
    Dataset authored and provided by
    SkyQuest Technology
    License

    https://www.skyquestt.com/privacy/https://www.skyquestt.com/privacy/

    Time period covered
    2023 - 2030
    Area covered
    Global
    Description

    Rheumatoid Arthritis Drugs Market size was valued at USD 59.031 billion in 2021 and is poised to grow from USD 60.02 billion in 2022 to USD 70 billion by 2030, growing at a CAGR of 1.72%

  5. R

    Rheumatoid Arthritis Drugs Market Report

    • marketreportanalytics.com
    doc, pdf, ppt
    Updated Mar 13, 2025
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Market Report Analytics (2025). Rheumatoid Arthritis Drugs Market Report [Dataset]. https://www.marketreportanalytics.com/reports/rheumatoid-arthritis-drugs-market-2126
    Explore at:
    doc, pdf, pptAvailable download formats
    Dataset updated
    Mar 13, 2025
    Dataset authored and provided by
    Market Report Analytics
    License

    https://www.marketreportanalytics.com/privacy-policyhttps://www.marketreportanalytics.com/privacy-policy

    Time period covered
    2025 - 2033
    Area covered
    Global
    Variables measured
    Market Size
    Description

    The Rheumatoid Arthritis (RA) drugs market, valued at $36.84 billion in 2025, is projected to experience robust growth, driven by a rising prevalence of rheumatoid arthritis globally, an aging population, and the increasing demand for effective treatment options. The market's Compound Annual Growth Rate (CAGR) of 7.5% from 2025 to 2033 indicates significant expansion over the forecast period. Key drivers include the development and adoption of novel biologics and small molecule drugs offering improved efficacy and safety profiles compared to traditional treatments. The growing awareness of RA and improved access to healthcare in emerging markets are further contributing factors. Market segmentation reveals a substantial portion attributed to biologics due to their superior therapeutic effects in managing severe RA. However, the market faces certain restraints, including high treatment costs, potential side effects associated with certain drugs, and the emergence of biosimilars impacting pricing dynamics for established biologics. The competitive landscape is shaped by the presence of major pharmaceutical companies aggressively pursuing innovative therapies and expanding market reach. Strategic partnerships, mergers and acquisitions, and focused research and development efforts are shaping the competitive dynamics within the market. The segmentation by drug class (Disease-modifying anti-rheumatic drugs (DMARDs), Nonsteroidal anti-inflammatory drugs (NSAIDs), Corticosteroids) and type (Biologics, Small Molecules) reflects the diverse treatment approaches available. North America currently holds a significant market share, primarily driven by high healthcare expenditure and advanced medical infrastructure in countries like the US. However, the Asia-Pacific region is expected to exhibit substantial growth due to increasing RA prevalence and rising healthcare spending in countries such as China. The European market remains significant, fueled by robust healthcare systems in countries like Germany and the UK. The continued focus on research and development of targeted therapies, along with the increasing demand for personalized medicine approaches, will likely shape future market growth. The strategic positioning of leading companies involves investments in clinical trials, regulatory approvals, and marketing campaigns to maintain a competitive edge. Industry risks involve potential regulatory hurdles, patent expirations, and the need for continuous innovation to meet evolving patient needs.

  6. m

    Global Rheumatology Drugs Market Share, Size & Industry Analysis 2033

    • marketresearchintellect.com
    Updated Aug 10, 2020
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Market Research Intellect (2020). Global Rheumatology Drugs Market Share, Size & Industry Analysis 2033 [Dataset]. https://www.marketresearchintellect.com/product/global-rheumatology-drugs-market-size-and-forecast/
    Explore at:
    Dataset updated
    Aug 10, 2020
    Dataset authored and provided by
    Market Research Intellect
    License

    https://www.marketresearchintellect.com/privacy-policyhttps://www.marketresearchintellect.com/privacy-policy

    Area covered
    Global
    Description

    Get key insights from Market Research Intellect's Rheumatology Drugs Market Report, valued at USD 45.2 billion in 2024, and forecast to grow to USD 68.1 billion by 2033, with a CAGR of 5.5% (2026-2033).

  7. t

    Rheumatoid Arthritis Drugs Market Demand, Size and Competitive Analysis |...

    • techsciresearch.com
    Updated Nov 9, 2023
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    TechSci Research (2023). Rheumatoid Arthritis Drugs Market Demand, Size and Competitive Analysis | TechSci Research [Dataset]. https://www.techsciresearch.com/report/rheumatoid-arthritis-drugs-market/17264.html
    Explore at:
    Dataset updated
    Nov 9, 2023
    Dataset authored and provided by
    TechSci Research
    License

    https://www.techsciresearch.com/privacy-policy.aspxhttps://www.techsciresearch.com/privacy-policy.aspx

    Description

    Global Rheumatoid Arthritis Drugs Market was valued at USD 59.20 billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 5.58%

    Pages181
    Market Size2024: USD 59.20 Billion
    Forecast Market Size2030: USD 81.33 Billion
    CAGR2025-2030: 5.58%
    Fastest Growing SegmentOver-the-counter
    Largest MarketNorth America
    Key Players1. AbbVie Inc. 2. Amgen Inc. 3. Bayer AG 4. Boehringer Ingelheim GmbH 5. Bristol-Myers Squibb Company 6. Celgene Corporation 7. F. Hoffmann-La Roche AG 8. Johnson & Johnson 9. Merck & Co. Inc. 10. Novartis AG

  8. Rheumatoid Arthritis Drugs Market Report | Global Forecast From 2025 To 2033...

    • dataintelo.com
    csv, pdf, pptx
    Updated Jan 7, 2025
    + more versions
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Dataintelo (2025). Rheumatoid Arthritis Drugs Market Report | Global Forecast From 2025 To 2033 [Dataset]. https://dataintelo.com/report/rheumatoid-arthritis-drugs-market
    Explore at:
    csv, pptx, pdfAvailable download formats
    Dataset updated
    Jan 7, 2025
    Dataset authored and provided by
    Dataintelo
    License

    https://dataintelo.com/privacy-and-policyhttps://dataintelo.com/privacy-and-policy

    Time period covered
    2024 - 2032
    Area covered
    Global
    Description

    Rheumatoid Arthritis Drugs Market Outlook



    The global rheumatoid arthritis drugs market size was estimated at $23.5 billion in 2023 and is projected to reach approximately $36.7 billion by 2032, growing at a compound annual growth rate (CAGR) of 5.1%. This growth can be attributed to several factors, including the rising prevalence of rheumatoid arthritis, advancements in drug development, and increasing awareness about the disease and its treatment options.



    One of the primary growth factors for the rheumatoid arthritis drugs market is the increasing incidence of the disease itself. According to the World Health Organization (WHO), rheumatoid arthritis affects about 1% of the global population, with a higher prevalence in women. As the global population ages, the number of individuals suffering from rheumatoid arthritis is expected to rise, thereby driving the demand for effective treatment options. Moreover, lifestyle factors such as smoking, obesity, and a sedentary lifestyle are known risk factors for developing rheumatoid arthritis, further contributing to the market's growth.



    Another significant growth driver is the continuous advancements in drug development and biotechnology. The pharmaceutical industry has made considerable strides in developing new and more effective drugs for managing rheumatoid arthritis. For instance, biologics and biosimilars have emerged as potent treatment options, offering better efficacy and fewer side effects compared to traditional medications. These advancements are expected to fuel the market growth over the forecast period. Additionally, the approval of new drugs by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) plays a crucial role in expanding the market.



    Increasing awareness about rheumatoid arthritis and its treatment options is another factor contributing to the market's growth. Public health initiatives, patient education programs, and the efforts of non-governmental organizations (NGOs) have significantly increased awareness about the disease. This, in turn, has led to an increase in the adoption of rheumatoid arthritis drugs, as more individuals are getting diagnosed and seeking treatment. Furthermore, the growing emphasis on early diagnosis and treatment to prevent disease progression is expected to enhance the demand for rheumatoid arthritis drugs in the coming years.



    Rheumatoid Arthritis and Lupus Treatments have seen significant advancements in recent years, particularly with the introduction of biologics and targeted therapies. These treatments have revolutionized the management of autoimmune diseases, offering patients more effective options with fewer side effects. The development of these therapies has been driven by a deeper understanding of the underlying mechanisms of autoimmune diseases, allowing for more precise targeting of the immune system. As research continues, the potential for new treatment options that can address both rheumatoid arthritis and lupus simultaneously is promising, providing hope for improved patient outcomes and quality of life.



    From a regional perspective, North America holds a significant share of the rheumatoid arthritis drugs market, owing to the presence of a well-established healthcare infrastructure, high healthcare expenditure, and a large patient population. The region is also home to several leading pharmaceutical companies engaged in the development of rheumatoid arthritis drugs. However, the Asia Pacific region is expected to witness the highest growth rate during the forecast period, driven by factors such as the increasing prevalence of rheumatoid arthritis, improving healthcare infrastructure, and rising awareness about the disease. Europe and Latin America are also anticipated to contribute significantly to the market growth, while the Middle East & Africa region is expected to witness moderate growth.



    Drug Type Analysis



    The rheumatoid arthritis drugs market is segmented by drug type into Disease Modifying Anti-Rheumatic Drugs (DMARDs), Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids, Biologics, and Others. DMARDs are a cornerstone in the treatment of rheumatoid arthritis, as they not only alleviate symptoms but also slow the disease progression. These drugs are often the first line of treatment recommended by healthcare providers and include both conventional synthetic DMARDs and targeted synthetic DMARDs. The effectiveness of DMARD

  9. F

    Rheumatoid Arthritis Drugs Market Size, Share, Growth Analysis Report By...

    • fnfresearch.com
    pdf
    Updated Jun 11, 2025
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Facts and Factors (2025). Rheumatoid Arthritis Drugs Market Size, Share, Growth Analysis Report By Administration Route (Oral and Parenteral), By Sales Channel (Over-The-Counter (OTC) and Prescription), By Molecule (Biopharmaceuticals (Biologics and Biosimilars), and Pharmaceuticals), and By Region - Global and Regional Industry Insights, Overview, Comprehensive Analysis, Trends, Statistical Research, Market Intelligence, Historical Data and Forecast 2022 – 2030 [Dataset]. https://www.fnfresearch.com/rheumatoid-arthritis-drugs-market
    Explore at:
    pdfAvailable download formats
    Dataset updated
    Jun 11, 2025
    Dataset authored and provided by
    Facts and Factors
    License

    https://www.fnfresearch.com/privacy-policyhttps://www.fnfresearch.com/privacy-policy

    Time period covered
    2022 - 2030
    Area covered
    Global
    Description

    [231+ Pages Report] The global rheumatoid arthritis drugs market size is expected to grow from USD 60.1 billion in 2021 to USD 70.1 billion by 2030, at a CAGR of 1.75% from 2022-2030

  10. c

    Global Rheumatology Drugs Market Report 2025 Edition, Market Size, Share,...

    • cognitivemarketresearch.com
    pdf,excel,csv,ppt
    Updated Apr 30, 2025
    + more versions
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Cognitive Market Research (2025). Global Rheumatology Drugs Market Report 2025 Edition, Market Size, Share, CAGR, Forecast, Revenue [Dataset]. https://www.cognitivemarketresearch.com/rheumatology-drugs-market-report
    Explore at:
    pdf,excel,csv,pptAvailable download formats
    Dataset updated
    Apr 30, 2025
    Dataset authored and provided by
    Cognitive Market Research
    License

    https://www.cognitivemarketresearch.com/privacy-policyhttps://www.cognitivemarketresearch.com/privacy-policy

    Time period covered
    2021 - 2033
    Area covered
    Global
    Description

    Global Rheumatology Drugs market size 2025 was XX Million. Rheumatology Drugs Industry compound annual growth rate (CAGR) will be XX% from 2025 till 2033.

  11. c

    Global Drugs for Rheumatoid Arthritis Market Report 2025 Edition, Market...

    • cognitivemarketresearch.com
    pdf,excel,csv,ppt
    Updated Apr 30, 2025
    + more versions
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Cognitive Market Research (2025). Global Drugs for Rheumatoid Arthritis Market Report 2025 Edition, Market Size, Share, CAGR, Forecast, Revenue [Dataset]. https://www.cognitivemarketresearch.com/drugs-for-rheumatoid-arthritis-market-report
    Explore at:
    pdf,excel,csv,pptAvailable download formats
    Dataset updated
    Apr 30, 2025
    Dataset authored and provided by
    Cognitive Market Research
    License

    https://www.cognitivemarketresearch.com/privacy-policyhttps://www.cognitivemarketresearch.com/privacy-policy

    Time period covered
    2021 - 2033
    Area covered
    Global
    Description

    Global Drugs for Rheumatoid Arthritis market size 2025 was XX Million. Drugs for Rheumatoid Arthritis Industry compound annual growth rate (CAGR) will be XX% from 2025 till 2033.

  12. t

    Rheumatoid Arthritis Drugs Global Market Report 2025

    • thebusinessresearchcompany.com
    pdf,excel,csv,ppt
    Updated Jan 13, 2025
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    The Business Research Company (2025). Rheumatoid Arthritis Drugs Global Market Report 2025 [Dataset]. https://www.thebusinessresearchcompany.com/report/rheumatoid-arthritis-drugs-global-market-report
    Explore at:
    pdf,excel,csv,pptAvailable download formats
    Dataset updated
    Jan 13, 2025
    Dataset authored and provided by
    The Business Research Company
    License

    https://www.thebusinessresearchcompany.com/privacy-policyhttps://www.thebusinessresearchcompany.com/privacy-policy

    Description

    Global Rheumatoid Arthritis Drugs market size is expected to reach $66.61 billion by 2029 at 2.3%, rising arthritis cases fueling market growth for rheumatoid arthritis drugs

  13. k

    India Rheumatoid Arthritis Drugs Market Outlook to 2028

    • kenresearch.com
    pdf
    Updated Jun 23, 2024
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Ken Research (2024). India Rheumatoid Arthritis Drugs Market Outlook to 2028 [Dataset]. https://www.kenresearch.com/industry-reports/india-rheumatoid-arthritis-drugs-market
    Explore at:
    pdfAvailable download formats
    Dataset updated
    Jun 23, 2024
    Dataset authored and provided by
    Ken Research
    License

    https://www.kenresearch.com/terms-and-conditionshttps://www.kenresearch.com/terms-and-conditions

    Area covered
    India
    Description

    Explore India Rheumatoid Arthritis Drugs Market insights, revenue, share, top players, and growth projections in this comprehensive market research report.

  14. A

    Anti-Rheumatic Drugs Report

    • datainsightsmarket.com
    doc, pdf, ppt
    Updated Dec 31, 2024
    + more versions
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Data Insights Market (2024). Anti-Rheumatic Drugs Report [Dataset]. https://www.datainsightsmarket.com/reports/anti-rheumatic-drugs-544311
    Explore at:
    doc, pdf, pptAvailable download formats
    Dataset updated
    Dec 31, 2024
    Dataset authored and provided by
    Data Insights Market
    License

    https://www.datainsightsmarket.com/privacy-policyhttps://www.datainsightsmarket.com/privacy-policy

    Time period covered
    2025 - 2033
    Area covered
    Global
    Variables measured
    Market Size
    Description

    The global anti-rheumatic drugs market, valued at USD XXX million in 2025, is projected to reach USD XXX million by 2033, growing at a CAGR of XX%. The increasing prevalence of rheumatic diseases, rising awareness about treatment options, and advancements in drug development drive the market. Expanding access to healthcare, particularly in emerging markets, along with favorable reimbursement policies, further supports growth. Major market players include Novartis, UCB, AbbVie, Bristol-Myers Squibb, Merck, HEYL Chemisch-pharmazeutische Fabrik, Roche, Johnson & Johnson, Amgen, and Pfizer. The market is witnessing significant consolidation, with leading pharmaceutical companies acquiring smaller players to expand their product portfolios and strengthen their presence in key regions. Strategic partnerships and collaborations for research and development are prevalent, as companies seek to enhance their pipeline and address unmet medical needs. Anti-rheumatic drugs are a group of medications that are used to treat the symptoms of rheumatoid arthritis (RA) and other inflammatory conditions. They work by reducing inflammation and pain, and by slowing the progression of the disease. The global anti-rheumatic drugs market is growing rapidly, and is expected to reach a value of over $20 billion by 2025. This growth is being driven by the increasing prevalence of RA, the development of new and more effective therapies, and the growing awareness of the benefits of anti-rheumatic drugs. Some of the key players in the anti-rheumatic drugs market include:

    Novartis UCB AbbVie Bristol-Myers Squibb Merck & Co. HEYL Chemisch-pharmazeutische Fabrik Roche Johnson & Johnson Amgen Pfizer GSK Sanofi Abbott Laboratories Teva Pharmaceutical Eli Lilly and Company Celltrion Astellas Pharma Simcere Daiichi Sankyo Asahi Kasei

  15. Z

    Rheumatoid Arthritis Drugs/Therapeutics Market Analysis By Drugs...

    • zionmarketresearch.com
    pdf
    Updated Jun 14, 2025
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Zion Market Research (2025). Rheumatoid Arthritis Drugs/Therapeutics Market Analysis By Drugs (Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroid, Disease-Modifying Antirheumatic Drugs (DMARDs), Janus Kinase (JAK) Inhibitors, Biologic Agents, Others), By Route of Administration (Oral, Parenteral, Topical, Others), By End-Users (Hospitals, Specialty Clinics, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others), and By Region: Global Industry Analysis, Size, Share, Growth, Trends, and Forecasts 2024-2032 [Dataset]. https://www.zionmarketresearch.com/report/rheumatoid-arthritis-drugs-therapeutics-market
    Explore at:
    pdfAvailable download formats
    Dataset updated
    Jun 14, 2025
    Dataset authored and provided by
    Zion Market Research
    License

    https://www.zionmarketresearch.com/privacy-policyhttps://www.zionmarketresearch.com/privacy-policy

    Time period covered
    2022 - 2030
    Area covered
    Global
    Description

    Global Rheumatoid Arthritis Drugs/Therapeutics market size earned $18.55 Bn in 2023 and is expected to $30.15 Bn by 2032, with a CAGR of 5.50%.

  16. m

    Global Rheumatoid Arthritis (RA) Drugs Market Analysis, Share & Industry...

    • marketresearchintellect.com
    Updated Aug 9, 2024
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Market Research Intellect (2024). Global Rheumatoid Arthritis (RA) Drugs Market Analysis, Share & Industry Outlook 2033 [Dataset]. https://www.marketresearchintellect.com/product/global-rheumatoid-arthritis-ra-drugs-market/
    Explore at:
    Dataset updated
    Aug 9, 2024
    Dataset authored and provided by
    Market Research Intellect
    License

    https://www.marketresearchintellect.com/privacy-policyhttps://www.marketresearchintellect.com/privacy-policy

    Area covered
    Global
    Description

    Stay updated with Market Research Intellect's Rheumatoid Arthritis (RA) Drugs Market Report, valued at USD 30.5 billion in 2024, projected to reach USD 45.2 billion by 2033 with a CAGR of 5.5% (2026-2033).

  17. R

    Rheumatoid Arthritis Drugs Industry Report

    • trueinsightsreports.com
    doc, pdf, ppt
    Updated Jun 8, 2025
    + more versions
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    True Insights Reports (2025). Rheumatoid Arthritis Drugs Industry Report [Dataset]. https://www.trueinsightsreports.com/reports/rheumatoid-arthritis-drugs-industry-8084
    Explore at:
    pdf, doc, pptAvailable download formats
    Dataset updated
    Jun 8, 2025
    Dataset authored and provided by
    True Insights Reports
    License

    https://www.trueInsightsreports.com/privacy-policyhttps://www.trueInsightsreports.com/privacy-policy

    Time period covered
    2025 - 2033
    Area covered
    Global
    Variables measured
    Market Size
    Description

    The Rheumatoid Arthritis (RA) drugs market, valued at approximately $XX million in 2025, is projected to experience robust growth, exhibiting a compound annual growth rate (CAGR) of 5.60% from 2025 to 2033. This expansion is fueled by several key drivers. The rising prevalence of rheumatoid arthritis globally, particularly in aging populations, creates significant demand for effective treatment options. Advancements in drug development, including the introduction of novel biologics and targeted therapies offering improved efficacy and reduced side effects, are also contributing to market growth. Furthermore, increased healthcare expenditure and improved access to healthcare in developing economies are expanding treatment accessibility, further boosting the market. However, high treatment costs associated with biologics and the potential for adverse events remain significant restraints. The market is segmented by molecule type (pharmaceuticals and biopharmaceuticals), drug class (NSAIDs, corticosteroids, analgesics, and others), and sales channel (prescription and over-the-counter). Biopharmaceuticals, particularly biologics, are anticipated to dominate the market due to their superior efficacy in managing RA symptoms. The prescription sales channel holds a substantial share, reflecting the need for physician oversight in managing this chronic condition. Geographically, North America and Europe currently hold significant market share, driven by high healthcare spending and established healthcare infrastructure. However, the Asia-Pacific region is projected to witness the fastest growth rate due to rising disease prevalence and increasing healthcare awareness. Key players in the market include Boehringer Ingelheim, Bayer, Celgene (now Bristol Myers Squibb), Novartis, Amgen, Merck, and other prominent pharmaceutical companies, continuously striving to develop and commercialize innovative RA treatments. The competitive landscape is characterized by intense research and development activities aimed at developing more efficacious and safer RA drugs. Companies are focusing on personalized medicine approaches to tailor treatment strategies based on individual patient characteristics and genetic profiles. Strategic alliances, mergers, and acquisitions are also prevalent, as companies seek to expand their product portfolios and market reach. The market will continue to evolve with the emergence of biosimilars, offering cost-effective alternatives to existing biologics. Regulatory approvals and pricing strategies will play a crucial role in shaping the market dynamics over the forecast period. The long-term outlook remains positive, driven by ongoing advancements in RA treatment, increasing disease prevalence, and expanding access to healthcare globally. However, the market's future success hinges on addressing the challenges of affordability and ensuring sustainable access to innovative therapies for all patients in need. Rheumatoid Arthritis Drugs Market Report: 2019-2033 This comprehensive report provides a detailed analysis of the Rheumatoid Arthritis Drugs industry, offering valuable insights for investors, manufacturers, and healthcare professionals. The study period covers 2019-2033, with a base year of 2025 and a forecast period of 2025-2033. The report leverages extensive market research and data analysis to offer a thorough understanding of market dynamics, competitive landscapes, and future growth potential. The global market size is predicted to reach xx Million by 2033. Recent developments include: In February 2022, the United States Food and Drug Administration (FDA) accepted for review the Prior Approval Supplement (PAS) to the Biologics License Application (BLA) for ABRILADA (adalimumab-afzb) as an interchangeable biosimilar to Humira (adalimumab)., In February 2022, Biogen Inc and Xbrane Biopharma AB entered a commercialization and license agreement to develop, manufacture, and commercialize Xcimzane. This preclinical monoclonal antibody is a proposed biosimilar referencing CIMZIA (certolizumab pegol) to treat rheumatoid arthritis.. Key drivers for this market are: Growing Preference Towards Development of Biologics and Biosimilars, Rising Burden of Arthritis. Potential restraints include: Patent Expiration of Blockbuster Drugs, Alternative Treatment Options. Notable trends are: NSAIDs Segment is Expected to Hold a Major Share Over the Forecast Period.

  18. m

    Rheumatoid Arthritis Drug Consumption Market Industry Size, Share & Insights...

    • marketresearchintellect.com
    + more versions
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Market Research Intellect, Rheumatoid Arthritis Drug Consumption Market Industry Size, Share & Insights for 2033 [Dataset]. https://www.marketresearchintellect.com/product/global-rheumatoid-arthritis-drug-consumption-market-size-and-forecast/
    Explore at:
    Dataset authored and provided by
    Market Research Intellect
    License

    https://www.marketresearchintellect.com/privacy-policyhttps://www.marketresearchintellect.com/privacy-policy

    Area covered
    Global
    Description

    Explore the growth potential of Market Research Intellect's Rheumatoid Arthritis Drug Consumption Market Report, valued at USD 30 billion in 2024, with a forecasted market size of USD 45 billion by 2033, growing at a CAGR of 5.5% from 2026 to 2033.

  19. Rheumatoid Arthritis Treatment Market Study by Symptomatic Treatment,...

    • factmr.com
    csv, pdf
    Updated Apr 15, 2024
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Fact.MR (2024). Rheumatoid Arthritis Treatment Market Study by Symptomatic Treatment, Intermediate Corticosteroid Therapy, Stem Cell Therapy, Disease Modifying and Anti-rheumatic Drugs from 2024 to 2034 [Dataset]. https://www.factmr.com/report/rheumatoid-arthritis-treatment-market
    Explore at:
    csv, pdfAvailable download formats
    Dataset updated
    Apr 15, 2024
    Dataset provided by
    Fact.MR
    License

    https://www.factmr.com/privacy-policyhttps://www.factmr.com/privacy-policy

    Time period covered
    2024 - 2034
    Area covered
    Worldwide
    Description

    Worldwide revenue from the sales of rheumatoid arthritis treatment solutions is estimated at US$ 35.84 billion in 2024 and is forecasted to increase at a CAGR of 6% to reach US$ 64.17 billion by the end of 2034.

    Report AttributesDetails
    Rheumatoid Arthritis Treatment Market Size (2024E)US$ 35.84 Billion
    Forecasted Market Value (2034F)US$ 64.17 Billion
    Global Market Growth Rate (2024 to 2034)6% CAGR
    Latin America Market Growth Rate (2024E)4.5% CAGR
    North America Market Share (2024E)43.4%
    Market Value of Hospitals Segment (2024E)US$ 30.16 Billion
    Key Companies Profiled
    • Boehringer Ingelheim GmbH
    • AbbVie
    • Regeneron Pharmaceuticals, Inc.
    • Novartis AG
    • Bristol-Myers Squibb Company
    • Pfizer Inc.
    • UCB S.A.
    • F. Hoffmann-La Roche Ltd.
    • Amgen, Inc.
    • Johnson & Johnson Services Inc.
    • Merck & Co. Inc.
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company

    Country-wise Insights

    AttributeUnited States
    Market Value (2024E)US$ 14.11 Billion
    Growth Rate (2024 to 2034)5.5% CAGR
    Projected Value (2034F)US$ 24.19 Billion
    AttributeBrazil
    Market Value (2024E)US$ 1.14 Billion
    Growth Rate (2024 to 2034)6.3% CAGR
    Projected Value (2034F)US$ 2.1 Billion

    Category-wise Insights

    AttributeDMARDs
    Segment Value (2024E)US$ 32.17 Billion
    Growth Rate (2024 to 2034)6% CAGR
    Projected Value (2034F)US$ 57.75 Billion
    AttributeHospitals
    Segment Value (2024E)US$ 30.16 Billion
    Growth Rate (2024 to 2034)6% CAGR
    Projected Value (2034F)US$ 54.21 Billion
  20. d

    Rheumatoid Arthritis Drugs Market - Market Size, Sustainable Insights and...

    • datamintelligence.com
    pdf,excel,csv,ppt
    Updated Jun 28, 2024
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    DataM Intelligence (2024). Rheumatoid Arthritis Drugs Market - Market Size, Sustainable Insights and Growth Report 2024-2031 [Dataset]. https://www.datamintelligence.com/research-report/rheumatoid-arthritis-drugs-market
    Explore at:
    pdf,excel,csv,pptAvailable download formats
    Dataset updated
    Jun 28, 2024
    Dataset authored and provided by
    DataM Intelligence
    License

    https://www.datamintelligence.com/terms-conditionshttps://www.datamintelligence.com/terms-conditions

    Area covered
    Global
    Description

    Rheumatoid Arthritis Drugs Market is expected to grow at a high CAGR during the forecast period 2024-2031

Share
FacebookFacebook
TwitterTwitter
Email
Click to copy link
Link copied
Close
Cite
Mordor Intelligence, Rheumatoid Arthritis Drugs Market Size & Share Analysis - Industry Research Report - Growth Trends [Dataset]. https://www.mordorintelligence.com/industry-reports/rheumatoid-arthritis-drugs-market

Rheumatoid Arthritis Drugs Market Size & Share Analysis - Industry Research Report - Growth Trends

Explore at:
pdf,excel,csv,pptAvailable download formats
Dataset authored and provided by
Mordor Intelligence
License

https://www.mordorintelligence.com/privacy-policyhttps://www.mordorintelligence.com/privacy-policy

Time period covered
2019 - 2030
Area covered
Global
Description

The Rheumatoid Arthritis Drugs Market report segments the industry into By Type Of Molecule (Pharmaceuticals, Biopharmaceuticals), By Drug Class (Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Disease-Modifying Antirheumatic Drugs (DMARDs), Corticosteroids, Analgesics, Other Drug Classes), By Sales Channel (Prescription, Over-The-Counter (OTC)), and Geography (North America, Europe, Asia-Pacific, and more).

Search
Clear search
Close search
Google apps
Main menu